Piper Sandler analyst Kelsey Goodwin lowered the firm’s price target on Black Diamond Therapeutics (BDTX) to $8 from $9 and keeps an Overweight rating on the shares. Following a flurry of updates from companies across its coverage, the firm updating its 2026 Catalyst Tracker, as well as several models and price targets.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
- Black Diamond Advances Silevertinib Combo Into Phase 2 for Hard‑to‑Treat Brain Cancer
- 3 Low P/E Ratio Stocks Poised to Surge Over 100% in 2026
- Promising Phase 2 Trial Results and Strategic Partnerships Support Buy Rating for Black Diamond Therapeutics
- Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim
- Promising Potential of Silevertinib in EGFR-Mutant NSCLC: Buy Rating Reiterated